IMPLANET: Completion of the First JAZZ Band Surgical Procedure in Brazil, Latin America’s Largest Market

Regulatory News:

IMPLANET (Paris:IMPL) (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, announces that the first idiopathic scoliosis surgical procedure using the JAZZ platform in Brazil has been successfully carried out by Dr. Raphael Pratali and his team at the Hospital do Servidor Público Estadual in São Paulo. Further surgical procedures are already scheduled in Brazil.

"JAZZ technology is an excellent alternative to screws in maximizing the correction of major spine deformities. Using JAZZ implants in a hybrid construct in idiopathic scoliosis surgery makes it possible to restore the patient’s sagittal balance. By significantly reducing operating time, we provide the patient with additional safety. I will obviously be using JAZZ technology during my surgical procedures from now on,” says Dr Pratali.

Alvaro Tadeus, CEO of Importek, Implanet’s commercial partner in Brazil, adds: "We are delighted by the unanimous consensus regarding this first surgical procedure, which was carried out by an eminent spine surgeon in Brazil. We will now be able to accelerate the marketing of JAZZ technology in this country, backed by our in-depth knowledge of the spine market, our network of influential opinion leaders and our specific sales structure.”

Ludovic Lastennet, CEO of Implanet, concludes: "We are impressed by how quickly the first JAZZ surgery was performed following the regulatory approval received two months ago from the Brazilian health authorities. I am pleased to hear that Dr. Pratali and his team are delighted with the advantages our technology has provided. This will no doubt enable its adoption to spread among peers in this market, which saw close to 27,000 vertebral fusion surgeries in 2015.”

Next financial press release: 2015 annual results, on 30 March 2016 (after market).

About IMPLANET
Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 45 staff and recorded 2015 sales of €6.7 million. For further information, please visit www.implanet.com.

Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013.
IMPLANET is listed on Compartment C of the Euronext™ regulated market in Paris.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160128006142/en/